Sanofi’s SAR402663 Granted Fast Track Designation for Neovascular AMD in the US
The U.S. Food and Drug Administration (FDA) has granted fast track designation to Sanofi’s investigational gene therapy SAR402663 for treating neovascular age-related macular…
Read More...
Read More...
